- Home
- FGL vs TPST Comparison
FGL vs TPST Comparison
Compare FGL & TPST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGL
- TPST
- Stock Information
- Founded
- FGL 2021
- TPST 2011
- Country
- FGL Malaysia
- TPST United States
- Employees
- FGL N/A
- TPST N/A
- Industry
- FGL
- TPST Biotechnology: Pharmaceutical Preparations
- Sector
- FGL
- TPST Health Care
- Exchange
- FGL NYSE
- TPST Nasdaq
- Market Cap
- FGL 33.2M
- TPST 27.2M
- IPO Year
- FGL 2024
- TPST N/A
- Fundamental
- Price
- FGL $1.87
- TPST $0.93
- Analyst Decision
- FGL
- TPST Strong Buy
- Analyst Count
- FGL 0
- TPST 4
- Target Price
- FGL N/A
- TPST $20.00
- AVG Volume (30 Days)
- FGL 1.1M
- TPST 1.8M
- Earning Date
- FGL 12-17-2024
- TPST 11-12-2024
- Dividend Yield
- FGL N/A
- TPST N/A
- EPS Growth
- FGL 45.69
- TPST N/A
- EPS
- FGL 0.04
- TPST N/A
- Revenue
- FGL $23,268,519.00
- TPST N/A
- Revenue This Year
- FGL N/A
- TPST N/A
- Revenue Next Year
- FGL N/A
- TPST N/A
- P/E Ratio
- FGL $49.55
- TPST N/A
- Revenue Growth
- FGL 336.06
- TPST N/A
- 52 Week Low
- FGL $1.25
- TPST $0.70
- 52 Week High
- FGL $5.26
- TPST $6.00
- Technical
- Relative Strength Index (RSI)
- FGL N/A
- TPST 54.03
- Support Level
- FGL N/A
- TPST $0.86
- Resistance Level
- FGL N/A
- TPST $1.05
- Average True Range (ATR)
- FGL 0.00
- TPST 0.08
- MACD
- FGL 0.00
- TPST 0.01
- Stochastic Oscillator
- FGL 0.00
- TPST 52.92
About FGL FOUNDER GROUP LTD
Founder Group Ltd acts as an end-to-end Engineering, Procurement, Construction, and Commissioning solutions provider for solar PV facilities in Malaysia. The segments of the company are large-scale solar projects and commercial and industrial (C&I) solar projects. Large-scale solar projects of the company are utility-scale solar PV power plants with installed generating capacity of 1 MWac or more, and C&I projects of the company are smaller-scale solar projects where the solar PV systems are installed on rooftops and are designed to generate electricity for commercial and industrial properties for their consumption at factories, warehouses, and commercial stores. The company derives its revenue from Malaysia.
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.